These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36774428)

  • 41. Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective.
    Li X; Warren S; Rozenbaum MH; Perdrizet J
    Infect Dis Ther; 2023 Mar; 12(3):997-1006. PubMed ID: 36867396
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
    Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
    J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of childhood pneumococcal conjugate vaccination on invasive disease in older adults of 10 European countries: implications for adult vaccination.
    Hanquet G; Krizova P; Valentiner-Branth P; Ladhani SN; Nuorti JP; Lepoutre A; Mereckiene J; Knol M; Winje BA; Ciruela P; Ordobas M; Guevara M; McDonald E; Morfeldt E; Kozakova J; Slotved HC; Fry NK; Rinta-Kokko H; Varon E; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Latasa P; Castilla J; Smith A; Henriques-Normark B; Whittaker R; Pastore Celentano L; Savulescu C;
    Thorax; 2019 May; 74(5):473-482. PubMed ID: 30355641
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of routine childhood immunization with higher-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal diseases and carriage: a systematic literature review.
    Tin Tin Htar M; van Den Biggelaar AHJ; Sings H; Ferreira G; Moffatt M; Hall-Murray C; Verstraeten T; Gessner BD; Schmitt HJ; Jodar L
    Expert Rev Vaccines; 2019 Oct; 18(10):1069-1089. PubMed ID: 31585049
    [No Abstract]   [Full Text] [Related]  

  • 46. Cost-effectiveness analysis of the 20-valent pneumococcal conjugate vaccine for the pediatric population in South Korea.
    Kang DW; June Choe Y; Lee JY; Suk IA; Kim YS; Kim HY; Byun BK; Park SK
    Vaccine; 2024 Jun; ():. PubMed ID: 38845302
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine for routine pediatric vaccination programs in Japan.
    Shinjoh M; Togo K; Hayamizu T; Yonemoto N; Morii J; Perdrizet J; Kamei K
    Expert Rev Vaccines; 2024; 23(1):485-497. PubMed ID: 38682661
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of health benefits and cost-effectiveness of 10-valent and 13-valent pneumococcal conjugate vaccination in Kenyan children.
    Ayieko P; Griffiths UK; Ndiritu M; Moisi J; Mugoya IK; Kamau T; English M; Scott JA
    PLoS One; 2013; 8(6):e67324. PubMed ID: 23826268
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluating the health and economic outcomes of a PCV15 vaccination program for adults aged 65 years-and-above in Switzerland.
    Owusu-Edusei K; Favre-Bulle A; Tsoumani E; Mutschler T; Cossrow N
    Vaccine; 2024 May; 42(13):3239-3246. PubMed ID: 38609806
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-Effectiveness of Pneumococcal Vaccination in Adults in Italy: Comparing New Alternatives and Exploring the Role of GMT Ratios in Informing Vaccine Effectiveness.
    Restivo V; Baldo V; Sticchi L; Senese F; Prandi GM; Pronk L; Owusu-Edusei K; Johnson KD; Ignacio T
    Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515068
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
    Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
    PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Towards the introduction of pneumococcal conjugate vaccines in Bhutan: A cost-utility analysis to determine the optimal policy option.
    Dorji K; Phuntsho S; Pempa ; Kumluang S; Khuntha S; Kulpeng W; Rajbhandari S; Teerawattananon Y
    Vaccine; 2018 Mar; 36(13):1757-1765. PubMed ID: 29478752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Invasive Pneumococcal Disease Epidemiology and Serotype Replacement After the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine in Ontario, Canada, 2007-2022.
    Grewal R; Hillier K; Deeks SL; Yeung AH; Wilson SE; Wijayasri S; Harris TM; Buchan SA
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae275. PubMed ID: 38868312
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea.
    Kang DW; Kim CR; Song JY; Park SK
    Vaccine; 2024 Feb; 42(4):871-878. PubMed ID: 38225184
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease Among Adults With HIV-United States, 2008-2018.
    Kobayashi M; Matanock A; Xing W; Adih WK; Li J; Gierke R; Almendares O; Reingold A; Alden N; Petit S; Farley MM; Harrison LH; Holtzman C; Baumbach J; Thomas A; Schaffner W; McGee L; Pilishvili T
    J Acquir Immune Defic Syndr; 2022 May; 90(1):6-14. PubMed ID: 35384920
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study.
    Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S
    Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.
    Kieninger MP; Caballero EG; Sosa AA; Amarilla CT; Jáuregui B; Janusz CB; Clark AD; Castellanos RM
    Vaccine; 2015 May; 33 Suppl 1():A143-53. PubMed ID: 25919155
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of PCV10, PCV13, PCV15, PCV20 and PPSV23 vaccine coverage of invasive Streptococcus pneumoniae isolate serotypes in Canada: the SAVE study, 2011-20.
    Schellenberg JJ; Adam HJ; Baxter MR; Karlowsky JA; Golden AR; Martin I; Demczuk W; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2023 May; 78(Suppl 1):i37-i47. PubMed ID: 37130588
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand.
    Dilokthornsakul P; Kengkla K; Saokaew S; Permsuwan U; Techasaensiri C; Chotpitayasunondh T; Chaiyakunapruk N
    Vaccine; 2019 Jul; 37(32):4551-4560. PubMed ID: 31280944
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt.
    Sevilla JP; Burnes D; El Saie RZ; Haridy H; Wasserman M; Pugh S; Perdrizet J; Bloom D
    Hum Vaccin Immunother; 2022 Nov; 18(6):2114252. PubMed ID: 36070504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.